A detailed history of Morgan Stanley transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Morgan Stanley holds 394 shares of LUCD stock, worth $299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
394
Previous 954 58.7%
Holding current value
$299
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.75 - $0.88 $420 - $492
-560 Reduced 58.7%
394 $0
Q2 2024

Oct 17, 2024

SELL
$0.67 - $1.04 $14 - $22
-22 Reduced 2.25%
954 $0
Q2 2024

Aug 14, 2024

SELL
$0.67 - $1.04 $14 - $22
-22 Reduced 2.25%
954 $0
Q1 2024

Oct 17, 2024

BUY
$0.81 - $1.52 $17 - $33
22 Added 2.31%
976 $0
Q1 2024

Aug 16, 2024

BUY
$0.81 - $1.52 $628 - $1,179
776 Added 388.0%
976 $0
Q1 2024

May 15, 2024

BUY
$0.81 - $1.52 $628 - $1,179
776 Added 388.0%
976 $0
Q4 2023

Aug 16, 2024

SELL
$1.16 - $1.54 $874 - $1,161
-754 Reduced 79.04%
200 $0
Q2 2023

Aug 14, 2023

SELL
$1.28 - $1.78 $768 - $1,068
-600 Reduced 75.0%
200 $0
Q1 2023

May 15, 2023

SELL
$1.17 - $1.77 $108 - $164
-93 Reduced 10.41%
800 $1,000
Q4 2022

Feb 14, 2023

SELL
$1.21 - $2.27 $22,216 - $41,679
-18,361 Reduced 95.36%
893 $1,000
Q3 2022

Nov 14, 2022

SELL
$1.53 - $3.45 $59,810 - $134,867
-39,092 Reduced 67.0%
19,254 $30,000
Q2 2022

Oct 27, 2022

BUY
$1.73 - $3.44 $84,972 - $168,962
49,117 Added 532.2%
58,346 $131,000
Q2 2022

Aug 15, 2022

BUY
$1.73 - $3.44 $84,972 - $168,962
49,117 Added 532.2%
58,346 $131,000
Q1 2022

Oct 27, 2022

SELL
$2.85 - $5.24 $139,983 - $257,373
-49,117 Reduced 84.18%
9,229 $31,000
Q1 2022

May 13, 2022

SELL
$2.85 - $5.24 $35,719 - $65,672
-12,533 Reduced 57.59%
9,229 $31,000
Q4 2021

Feb 14, 2022

BUY
$4.87 - $11.76 $105,980 - $255,921
21,762 New
21,762 $116,000

Others Institutions Holding LUCD

About Lucid Diagnostics Inc.


  • Ticker LUCD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 38,568,500
  • Market Cap $29.3M
  • Description
  • Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...
More about LUCD
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.